Assays

Agilent Adds Liquid Biopsy Assay

Acquisitions, Assays, Breakthrough Device Designation, Business, Diagnostic Tools, Liquid Biopsies, Precision Oncology, Testing, Tissue

Agilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.

March 2, 2021/by Andrew Humphreys

Caris Life Sciences Secures $310 Million to Advance Precision Medicine Toolset

Business, DNA, Genomic Data, Growth Capital, Molecular Profiling Assays, Oncology, Precision Medicine, Private Equity, Proteins, R&D, RNA

Caris Life Sciences secured $310 million in growth capital that will be used to expand the molecular science company’s presence in precision medicine in oncology.

October 27, 2020/by Andrew Humphreys

Screening Approaches for Reducing Attrition Due to Drug-induced Liver Injury (DILI) Early in Drug Discovery

Business, Cells, Drug Discovery, Hepatotoxicity, In Vitro Assays, Liver Injury, Mitochondrial Dysfunction, Webinars

This webinar will discuss a set of in vitro assays that tackle the challenges of in vitro hepatotoxicity assessment.

May 23, 2020/by Administrator

FDA Approves Use of Ortho’s High-Throughput, Automated COVID-19 Antibody Test

Antibody Assays, Antibody Tests, Approvals, Emergency Use Authorization, FDA, FDA/Regulatory

The U.S. Food and Drug Administration granted Ortho Clinical Diagnostics’ total antibody assay for COVID-19 Emergency Use Authorization.

April 15, 2020/by BioSpace

Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

Advanced Non-Small Cell Lung Cancer, Assays, Biomarkers, Business, Clinical Trials, Collaborations, Gene Expression, Genomes, Liquid Biopsies, Oncology, Tumor Biopsies, Tumors

Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).

January 3, 2019/by Business Wire

Personal Genome Diagnostics and KingMed Enter Strategic Partnership to make Comprehensive Genomic Tissue Panel with TMB available in China and Hong Kong

Assays, Business, Cancer, Cancer Genomics, Gene Testing, Genome Sequencing, Genomes, Immuno-oncology, Partnerships, Tumors

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and KingMed Diagnostics, a laboratory services leader in China, announced that they have entered into a strategic partnership for the PGDx elioTM tissue complete assay.

January 3, 2019/by Business Wire

Reaction Biology launches ion channel division

Assays, Biochemicals, Business, Contract Research Organization (CRO), Drug Discovery, Ions, Launches

Reaction Biology Corporation, a leading contract research organization providing early-stage drug discovery services, announced that it has launched a new division to provide ion-channel discovery services.

January 31, 2018/by Administrator